Clinical Trial Update: Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intravenous Alvespimycin in HER2-positive breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alvespimycin (alvespimycin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED